Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Affordable Care Act
    • Consumer-Driven Health Care
      • Cost of Healthcare
      • COVID-19 and Public Health
      • Doctors & Hospitals
      • Public Insurance
      • Policy & Legislation
    • Direct Primary Care
    • Drug Prices & Regulations
    • Health Economics & Costs
    • Health Insurance
    • Health Reform
    • Medical Tourism
    • Medicare
    • Single-Payer/Medicare-for-All
    • Telemedicine
  • Goodman Institute
  • Contact
The Goodman Institute Health Blog

Drug Makers File Hundreds of Bogus Patents to Block Generic Competition

Posted on September 16, 2022 by Devon Herrick

A report by the Initiative for Medicines, Access & Knowledge (I-MAK) released a report on patent abuse and so-called gaming of the patent system. I-MAK is a nonprofit organization that advocates drug patent reform.

Four pharmaceutical companies have filed hundreds of patents to keep their drugs out of the hands of generic competition and prolong their “unprecedented profits,” according to a report published Thursday.

U.S. patent law rewards innovation by granting an exclusive right to manufacture a drug for a period of 20 years. Some of the 20-year period is used bringing the drug to market, however. Once the exclusive period is up, generic drug makers are allowed to produce the drug. However, drug companies often tweak the drug and file new patents in a process called “evergreening.”

It’s an approach seen across the pharmaceutical industry: drug companies file, on average, more than 140 patent applications per drug, according to the I-MAK report. Out of those patent applications, 66% of them were filed after the Food and Drug Administration approved the drug to be on the market.

These extra patents are “absolutely” to extend their monopolies, said Arthur Caplan, the head of the Division of Medical Ethics at NYU Langone Medical Center.

While the practice of evergreening isn’t necessarily illegal, said Caplan, who was also not involved with the report, it is unethical. “It’s clear that the system is being manipulated and we need to be rethinking the rules of patenting.”

The drug Humira, used to treat rheumatoid arthritis, is owned by the biotech firm AbbVie. Sales of Humira amounted to $17.3 billion in 2021. The original patent on Humira expired in 2016 but AbbVie filed 311 patent applications for the drug to extend it’s patent life. Nearly 300 of these patent applications (94%) were filed after the U.S. Food and Drug Administration (FDA) approved the drug. Humira now won’t face competition until 2023.

The practice of extending patents doesn’t always go unchallenged. In some cases, generic manufacturers sue the drugmakers to get their drugs on the market, Lemley said. However, he added, those lawsuits often end in settlements between the companies.

Settling the lawsuit is “essentially paying the generic to go away,” Lemley said.

The United States Patent and Trademark Office is working to prevent unjustifiably delays to generic competition.

In the meantime, Caplan said he expects to see more litigation from the Department of Justice challenging the extra patents from drug companies.

Some experts believe the federal government should raise the bar for what is considered an improvement in an existing drug and decline frivolous patent extensions.

Join the conversation. Cancel reply

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 9 other subscribers

Popular Topics

©2023 The Goodman Institute Health Blog | Website by Lexicom